In vivo efficacy of ny-eso-1 plus adjuvant
AssigneeCSL Limited Ludwig Institute for Cancer Research
InventorsJonathan Cebon, Ian Davis, Weisan Chen, Simon Green
Life of this patent
Estimating the term…
Abstract
The invention relates to the discovery that administration of NY-ESO-1 protein, in combination with a saponin based adjuvant leads to an unexpectedly strong immune response against NY-ESO-1 expressing cells. Preferably, the combination is administered intramuscularly.
Claims33
Immunogenic composition comprising NY-ESO-1 protein and a saponin based adjuvant.
An isolated peptide comprising at least amino acids 89-99 of NY-ESO-1 and consisting of no more than amino acids 85-102 of NY-ESO-1.
An isolated peptide consisting of amino acids 89-100 of NY-ESO-1.
An isolated peptide consisting of amino acids 86-99 of NY-ESO-1.
A method for treating a subject suffering from or in need of prophylaxis for a cancer, cells of which express NY-ESO-1, comprising administering to said subject an amount of a composition containing NY-ESO-1 protein and a saponin based adjuvant, sufficient to induce an antibody response to NY-ESO-1 in said subject.
Dependencies are inferred from the claim text.